

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
US Department of Commerce  
United States Patent and Trademark  
Office, PCT  
2011 South Clark Place Room  
CP2/5C24  
Arlington, VA 22202  
ETATS-UNIS D'AMERIQUE  
in its capacity as elected Office

Date of mailing (day/month/year) 14 May 2001 (14.05.01)	
International application No. PCT/US00/19430	Applicant's or agent's file reference 7024474P116
International filing date (day/month/year) 17 July 2000 (17.07.00)	Priority date (day/month/year) 16 July 1999 (16.07.99)
Applicant THOMPSON, David, H. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
13 February 2001 (13.02.01)

☐ in a notice effecting later election filed with the International Bureau on:  
\_\_\_\_\_

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Claudio Borton Telephone No.: (41-22) 338.83.38
---	--

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number  
**WO 01/05375 A1**

(51) International Patent Classification<sup>7</sup>: A61K 9/127

(21) International Application Number: PCT/US00/19430

(22) International Filing Date: 17 July 2000 (17.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/144,301 16 July 1999 (16.07.1999) US  
60/146,552 30 July 1999 (30.07.1999) US

(71) Applicant (*for all designated States except US*): PURDUE RESEARCH FOUNDATION [US/US]; Office of Technology Transfer, 1063 Hovde Hall, West Lafayette, IN 47907 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): THOMPSON, David, H. [US/US]; 230 Spring Valley Lane, West Lafayette, IN 47906 (US). BOOMER, Jeremy, A. [US/US]; 1124 Johnson Drive, Apt. 3516, Buffalo Grove, Illinois 60089 (US). HAYNES, Robert [US/US]; 533 Powell Drive, Annapolis, MD 21401 (US).

(74) Agents: TUCKER, R., Craig et al.; Woodard, Emhardt, Naughton, Moriarty & McNett, Bank One Center/Tower, Suite 3700, 111 Monument Circle, Indianapolis, IN 46204 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: VINYL ETHER LIPIDS WITH CLEAVABLE HYDROPHILIC HEADGROUPS

(57) Abstract: A novel amphiphilic lipid compound having a cleavable, vinyl ether linked hydrophilic headgroup is described. Also described are liposomes containing the vinyl ether lipid compound, which may be triggered to release their contents and/or permeabilize or fuse with target lipid membranes. The cleavable vinyl ether linkage allows the hydrophilic headgroup to be dissociated from the hydrophobic tailgroup(s) of the lipid compound to facilitate phase transitions in the lipid bilayer.



WO 01/05375 A1

## VINYL ETHER LIPIDS WITH CLEAVABLE HYDROPHILIC HEADGROUPS

This application claims priority to U.S. Provisional Patent Application No. 60/144,301, filed July 16, 1999 and U.S. Provisional Patent Application No. 5 60/146,552, filed July 30, 1999.

### BACKGROUND OF THE INVENTION

This invention relates to novel amphiphilic compounds with cleavable hydrophilic headgroups and their use in liposomes. More particularly, the invention 10 relates to novel lipid compounds with hydrophilic headgroups linked to the molecule through a vinyl ether linkage, and their use in liposome vesicle formation and the triggered release of the liposomal contents or triggered permeabilization of, or fusion with, target lipid membranes. In another aspect, the invention also relates to triggered cleavage of the headgroups of novel vinyl ether lipid compounds while incorporated in 15 liposomes, to facilitate a phase transition of the liposome to effect the release of liposomal contents and/or the permeabilization of, and/or fusion with, cellular membranes by the liposomes.

Liposomes have been used as drug delivery vehicles with both passive and active-targeting schemes to attempt to site-specifically deliver the contents of the 20 liposome to target tissues *in vivo* as well as in cell and tissue culture applications. A significant drawback of previous methods of liposomal delivery systems has been constructing liposomes that have sufficient cell culture or *in vivo* stability to reach desired tissue sites and/or intra-cellular compartments, but will then efficiently release their contents once at the target site.

25 A wide variety of liposomal release mechanisms activated by light, heat, low pH, or enzymatic activity have been reported and reviewed. See Gerasimov, O.V., Rui, Y., and Thompson, D.H., *Triggered Release from Liposomes Mediated by Physically and Chemically Induced Phase Transitions*, Vesicles, Morton Rosoff, ed., Marcel Dekker, Inc., New York, 1996. One such method described in U.S. 30 Patent No. 5,277,913 provides for triggered phase changes in liposomes containing plasmalogen or plasmalogen analogs to cause release of the liposomal contents. In that disclosure, the vinyl ether linkage bonding one or both of the hydrophobic tailgroups of the lipids forming the liposome is cleaved by low pH conditions or by oxidation mediated by photoactive sensitizer agents. The cleavage results in one or

both of the hydrophobic tailgroups dissociating from the molecule, which causes local changes in the liposome structure leading to leaking of liposomal contents or to fusing of the liposome with adjacent membranes. However, these lipids, with labile vinyl ether linkages joining the hydrophobic tail groups to the remainder of the molecule, have limited sensitivity to desirable triggering conditions, as exhibited by slow liposomal content release rates and/or slow membrane fusion kinetics, to be optimal for many applications. One theory for this is that the labile vinyl ether linkage may distribute in the hydrophobic region of lipid bilayers, where access to protons and oxidative agents is limited.

In that no liposome structure has been found to date that is optimal for all applications, there is a need for new liposome compositions which remain stable *in vivo* and cell culture until they reach their desired target tissues or cellular compartments, whereupon they may be efficiently triggered to release their contents and/or to permeabilize or fuse with target membranes to deliver the liposomal contents into desired sites. It has been surprisingly found that the vinyl ether lipids of the present invention, having cleavable hydrophilic headgroups, facilitate liposome vesicle formation, and when cleaved under specific conditions at desirable target sites, facilitate liposomal content release and/or permeabilization of or fusion with target membranes.

## SUMMARY OF THE INVENTION

It is an object of the present invention to provide novel amphiphilic lipid compounds having acid or oxidatively labile vinyl ether linked hydrophilic headgroups which may be cleaved from the compound by oxidation or acid hydrolysis.

It is an object of another aspect of the present invention to provide lipid vesicles or liposomes containing two or more species, or types, of lipid molecules, at least one of which is a vinyl ether lipid having a cleavable hydrophilic headgroup. In a preferred embodiment of this aspect of the invention, the cleavable hydrophilic headgroups of the vinyl ether lipids cleave from the remainder of the molecule under oxidative and/or acidic conditions and the dissociation of the hydrophilic headgroups causes a local phase transition in the lipid bilayer.


In yet another aspect of the present invention it is an object to provide methods of delivering the contents of a liposome to target tissues, or across a target lipid bilayer membrane by contacting the tissue or lipid bilayer membrane under acidic and/or oxidative conditions, with a liposome comprising at least one type of lipid compound  
5 having a cleavable, vinyl ether linked hydrophilic headgroup, under which conditions the hydrophilic headgroups will dissociate from the remainder of the lipid compounds and thereby facilitate the permeabilization of and/or membrane fusion with the target lipid bilayer membrane, thereby releasing the contents of the liposome.

Various of these and other objects are achieved by the vinyl ether lipids with  
10 cleavable hydrophilic headgroups according to the present invention and their use in forming liposomes and the use of such liposomes to deliver desired therapeutic or diagnostic agents to desired tissues or cellular sites.

In one aspect of the present invention there are provided novel amphiphilic lipid compounds having a hydrophilic headgroup portion which is linked to the  
15 remainder of the molecule through a vinyl ether linkage, and a hydrophobic tailgroup portion, effective to anchor the compound in a lipid film or lipid bilayer membrane.

In a preferred embodiment of the invention, the hydrophilic headgroup is bonded to one double bonded carbon of the vinyl group and the ether oxygen is bonded to the other double bonded carbon in the vinyl group. In another preferred  
20 embodiment, one or more hydrophobic tailgroups are bonded either directly to the ether oxygen, or bonded by an ether or ester linkage to a polyalcohol or other linking moiety, which is bonded directly to the ether oxygen. In another preferred embodiment, each of said one or more hydrophobic tailgroups is independently selected from the group consisting of sterol, fatty acid ester, fatty alcohol, sphingosine,  
25 ceramide, phosphoglycerolipid, polyisoprenoid, and aryl ether.

In another aspect of the present invention there are provided vinyl ether lipid compounds of the formula



wherein one of either  $R^1$  or  $R^2$  is a hydrophilic headgroup and the other is hydrogen, a second hydrophilic headgroup, or a crosslinker joining one or more other molecules of the vinyl ether lipid compound, each at the  $R^1$  or  $R^2$  position;  $R^3$  is an organic  
5 hydrophobic moiety; and  $R^4$  is hydrogen or an electron donating group.

In another aspect of the present invention there are provided liposomes containing two or more species, or types, of lipids, at least one of which is a vinyl ether lipid as described above. The liposome may optionally contain a therapeutic agent or diagnostic agent, which is desired to be transported to and released in a target  
10 tissue or across a target lipid bilayer membrane.

In another aspect of the present invention there are provided methods of delivering therapeutic or diagnostic agents to predetermined tissues or across biological membranes by contacting said tissue or cell under oxidative or acidic conditions with a liposome encapsulating the desired agent in a liposome, said  
15 liposome comprising at least two different species of lipid compounds, at least one of said lipid compounds being an amphiphilic lipid compound having a acid or oxidatively labile vinyl ether linked hydrophilic headgroup, said acid or oxidative conditions being effective for cleaving said hydrophilic headgroup from the compound.

20 Related objects and advantages of the present invention will be apparent from the following detailed description of the preferred embodiments.

### **BRIEF DESCRIPTION OF THE FIGURES**

Figure 1 is a flow chart for the synthesis of CVEP.

Figure 2 is a flow chart for the synthesis of DVEP.

5        Figure 3 is a comparison of calcein release from CVEP:DOPE liposomes under acidic conditions.

Figure 4 is a comparison of the release of calcein from DOPE liposomes containing varying concentrations of CVEP.

10       Figure 5 is a comparison of calcein release from CVEP:DOPE liposomes under acidic conditions in the presence of sink liposomes.

Figure 6 is a comparison of photooxidatively triggered calcein release from CVEP:DOPE liposomes.

Figure 7 is a flow chart of an alternative synthetic method for CVEP.



## DESCRIPTION OF THE PREFERRED EMBODIMENTS

For purposes of promoting and understanding the principals of the invention reference will now be made to specific preferred embodiments and specific language  
5 will be used to describe the same. These specific descriptions of preferred embodiments are meant by way of illustration only, rather than as limitations on the scope of the present invention. Any alterations and modifications in the described invention, and any further applications of the principals of the invention as illustrated therein are contemplated as would normally occur to one skilled in the art to which the  
10 invention relates.

Abbreviations used herein are as follows:

CVEP is 1'-(4'-cholesteryloxy-3'-butenyl)- $\omega$ -methoxy-  
polyethylene[112] glycolate,  
BVEP is (R)-1,2-di-O-(1'Z,9'Z-octadecadienyl)-glycerol-3-( $\omega$ -methoxy-  
15 polyethylene[112] glycolate  
DOPE is 1,2-dioleoyl-*sn*-glycerophosphoethanolamine  
DMAP is N,N-dimethyl-4-aminopyridine  
EDCI is ethyldimethylaminopropyl carbodiimide  
THF is tetrahydrofuran  
20 DMF is dimethylformamide  
TBAF is tetrabutylammonium fluoride  
TOAB is tetraoctylammonium bromide  
TLC is thin layer chromatography

As used herein, "amphiphilic" describing a molecule, means having both a  
25 water-soluble polar head (hydrophilic) portion and a water-insoluble organic tail (hydrophobic) portion.

As used herein, "lipid" is an inclusive term for fats and fat derived materials, including compounds which are or are related to glycerol esters and ethers, fatty acid esters, fatty alcohols, sterols, and waxes. They may be hydrophobic, or amphiphilic.  
30 When amphiphilic, the hydrophilic headgroup may be bonded directly to a



hydrophobic tailgroup, such as a sterol, fatty acid or fatty alcohol, or the hydrophilic headgroup may be bonded to one or more hydrophobic tail groups through a linker group, such as, but not limited to a glycerol moiety.

As used herein, "vinyl ether" means a moiety in a compound having two  
5 carbon atoms bonded to each other by a carbon-carbon double bond, and at least one ether oxygen bonded to one of said double-bonded carbons atoms.

As used herein, acidic or oxidative conditions for triggering cleavage of the labile vinyl ether bond are to be understood as biologically suitable acidic or oxidative conditions; i.e. conditions compatible with biological systems.

10 The amphiphilic lipid compounds of the present invention comprise a hydrophobic tail portion effective for anchoring the compound in a lipid mono- or bilayer, a linking segment, which is a vinyl ether moiety bonded through the ether oxygen to the hydrophobic tail portion, and a hydrophilic headgroup bonded to the vinyl ether moiety either cis- or trans- to the vinyl ether oxygen. The hydrophilic  
15 headgroup of a vinyl ether lipid compound of the present invention may be cleaved from the remainder of the compound by oxidation or acid hydrolysis of the ether bond.

In one preferred embodiment, the hydrophilic headgroups of the amphiphilic compounds are cis to the ether oxygen. The cis isomers advantageously tend to be 3-10 times more reactive than their corresponding trans-isomers. Mixtures of cis- and  
20 trans-isomers may be used and may be blended to advantage to custom tailor the average rate of cleavage of the vinyl ether lipids in a population of liposomes to suit a given application.

Likewise, the hydrophobic and hydrophilic portions of amphiphilic lipids of the present invention may be selected to tailor the lipid to a given application.  
25 Hydrophobic tailgroups may be bonded directly to the vinyl ether oxygen of the linking portion of the compound. Alternatively, one or more hydrophobic groups may be bonded to a bridging moiety, which is bonded directly to the vinyl ether oxygen of the linking portion of the compound. By way of example, but without limitation, one or more hydrophobic tailgroups may be bonded through ether or ester linkages to a  
30 polyalcohol, as for example glycerol, butane-1,4-diol, or a mono-, di-, or tri-saccharide

moiety, which bridging moiety is then bonded to the vinyl ether oxygen of the linking portion of the compound.


Preferred hydrophobic tailgroups include, but are not limited to, fatty acids and fatty alcohols, particularly C<sub>5</sub>-C<sub>32</sub> saturated and mono- or poly-unsaturated fatty acids and alcohols; sterols, particularly cholesterol and its derivatives, as for example, but without limitation, ergosterol, stigmasterol, sitosterol, lanosterol, pregnenolone, cortisol, estradiol, aldosterone, cholecalciferol, and cholic acid; sphingosine; ceramide, phosphoglycerolipids, polyisoprenoids; and aryl ethers, particularly phenolic ethers. Particularly preferred are cholesterol and its derivatives, and glycerol diesters of fatty acids, particularly of C<sub>10</sub>-C<sub>24</sub> fatty acids, glycerol diethers of fatty alcohols, particularly of C<sub>10</sub>-C<sub>24</sub> fatty alcohols, and glycerol mixed ether/esters of fatty acids and alcohols, particularly of C<sub>10</sub>-C<sub>24</sub> fatty acids and alcohols. It is to be understood that the hydrophobic portion of lipids of the present invention may also be other amphiphilic lipids, particularly naturally occurring lipids, as for example, but without limitation, phospholipids and sphingolipids, provided that the resulting amphiphilic compound is effective in inducing lamellar phase lipid bilayers, and that when the vinyl ether bond is cleaved, the dissociation of the hydrophilic headgroup effects a phase transition which destabilizes the lamellar phase, resulting in liposome leakage or permeabilization of or fusion with a target membrane.

Oxidative conditions suitable for cleaving the hydrophilic headgroup include but are not limited to the generation of singlet oxygen by photoexcitation of oxidative sensitizer agents, as for example, but without limitation, bacteriochlorophyll *a* illuminated with near-infrared radiation at between about 670 nm and about 900 nm. Other suitable oxidative sensitizers include, without limitation, metallophthalocyanines, cyanines, metalloporphyrins, phthalocyanines, porphyrins, phenanthrazinequinones, purpurins, chlorins, and other dyes which generate singlet oxygen, such as Rose Bengal, etc, each illuminated by radiation of a wavelength within their respective absorption bands. Sensitizers can be introduced into the target tissues directly, or, in a preferred embodiment, by encapsulating the sensitizer in liposomes formed in part with the vinyl ether lipids of the present invention.

Several *in vivo* tissues and sub-cellular compartments also have oxidative environments able to cleave the hydrophilic headgroups of the lipid compounds of the present invention, as for example, but without limitation, phagosomes, activated macrophages, lymphocytes, neutrophils, stratum corneum, epidermis tissue, dermis tissue, and subdermal tissue, and neurons undergoing demyelination.


Acidic conditions suitable for acid hydrolysis of the vinyl ether bond to dissociate the hydrophilic headgroups of the amphiphilic lipid compounds of the present invention include pH less than or equal to 6.5, preferably pH less than or equal to 5.5, and more preferably pH less than or equal to 4.5. Such conditions are typically found in cellular endosomes, ischemic tissues, skin tissues, and tissues in the gastrointestinal tract, among other tissues. Thus, the cleavage of the vinyl ether linked hydrophilic headgroups of lipids of the present invention contained in liposomes may be advantageously triggered by the endocytosis of the liposome followed by the natural acidification of the endosome, leading to the release of the liposomal contents, or depending on the selected liposomal composition, the fusing of the liposomal membrane with the endosomal membrane resulting in the delivery of the liposomal contents into the cytoplasm of the cell.

In another aspect of the present invention there are provided vinyl ether compounds of the formula





wherein one of either  $\text{R}^1$  or  $\text{R}^2$  is a hydrophilic headgroup and the other is hydrogen, a second hydrophilic headgroup, or a crosslinker joining at least one other molecule of the vinyl ether lipid compound at the  $\text{R}^1$  or  $\text{R}^2$  position;  $\text{R}^3$  is an organic hydrophobic moiety; and  $\text{R}^4$  is hydrogen or an electron donating group.

Preferred vinyl ether lipid compounds of this aspect of the invention include compounds wherein  $R^3$  is selected from the group consisting of cholesterol, a cholesterol derivative, sphingosine, a sphingosine derivative, and a group of the formula



5

wherein each  $R^5$  is independently a hydrophobic group of the formula



, or



10

wherein  $n$  is an integer from 5 to 32 inclusive;  $y$  is an even integer from 2 to 12 inclusive, and wherein  $y$  is less than or equal to  $n$ .

Other hydrophobic tail groups are known in the art and are suitable for linkage through the ether oxygen of the lipid compounds of the present invention to provide a hydrophobic anchor for the compound in liposomes or other lipid mono- or bilayers.

In alternative embodiments of the present invention,  $R^4$  may be either hydrogen or an electron donating group. Electron donating groups enhance the lability of the ether linkage to the hydrophobic tailgroup portion of the compound. Those skilled in the art may select electron donating groups to tailor the acid and/or oxidative lability of the vinyl ether lipid compound to suit a particular usage. The skilled artisan may tailor the compound to cleave at a higher or lower pH and/or under greater or

lesser oxidative conditions, and thereby better control the tissue or cellular location of cleavage and the rate of cleavage of the amphiphilic lipid compounds used in a given liposome population. This advantageously allows for the finer control of the rate of release of liposomal contents and/or the permeabilization of or membrane fusion with target membranes by liposomes containing the present vinyl ether lipid compounds to suit a particular application. Examples of suitable electron donating groups include, but are not limited to, C<sub>1</sub>-C<sub>6</sub> alkoxy, preferably C<sub>1</sub>-C<sub>3</sub> alkoxy, furan, thiophene, and mono-, di- or tri- C<sub>1</sub>-C<sub>2</sub> alkoxy substituted phenyl.

The hydrophilic headgroups of the vinyl ether lipid compounds of the present invention are hydrophilic moieties effective in producing an amphiphilic compound with the selected hydrophobic tail group(s) so as to induce formation of liposomes with other lipids which do not otherwise form stable liposomes under the desired target conditions. The hydrophilic headgroups are likewise effective in stabilizing liposomes in the lamellar phase prior to the cleavage of the headgroups from the compounds. It is to be understood that when R<sup>1</sup> and R<sup>2</sup> are both hydrophilic headgroups, they are each independently selected from the same set of suitable hydrophilic headgroups.

Exemplary hydrophilic headgroups include, but are not limited to, naturally occurring lipid hydrophilic headgroups, substituted and unsubstituted poly(ethylene glycol), water-soluble polymers with a molecular weight of about 10,000 or less, amino substituted carbamates, mono-, di-, tri-, and oligosaccharides. Preferred hydrophilic headgroups include poly(ethylene glycol), C<sub>1</sub>-C<sub>6</sub> alkoxy poly(ethylene glycol), poly(ethylenimine), N,N-di(aminoethyl)carbamyloxyethyl-, choline, monosaccharide, disaccharide, ethanolamine, phosphatidylcholine, phosphatidylethanolamine, cardiolipin, phosphatidylmonosaccharides, such as phosphatidylinositol, and phosphatidyldisaccharides. Particularly preferred hydrophilic headgroups include poly(ethylene glycol) and C<sub>1</sub>-C<sub>6</sub> alkoxy terminated poly(ethylene glycol) and N,N-di(aminoethyl)carbamyloxyethyl-.

In one preferred embodiment useful in inducing liposome vesicle formation and stabilizing liposomes circulating in cell culture or *in vivo* prior to triggered

cleavage of the hydrophilic headgroup, the hydrophilic headgroup is a poly(ethylene glycol) chain containing an average of between 1 and about 300 glycol units, more preferably an average of between about 10 to about 150 glycol units. In another embodiment, the poly(ethylene glycol) chain contains an average of between about 40  
5 to about 125 glycol units.

When either  $R^1$  or  $R^2$  is a crosslinker group to another molecule of the vinyl ether lipid compound, two or more lipid compounds according to the present invention may be crosslinked together to obtain a cascading amplification effect. In such an embodiment, the vinyl ether bonds of all the crosslinked molecules would need to be  
10 cleaved before the hydrophilic headgroups would dissociate, but then the large number of headgroups dissociating at once induce a larger, potentially more instantaneous, effect on the local membrane structure.

When molecules of vinyl ether lipid compounds of the present invention are crosslinked in this manner, the crosslinker moiety bonds to the individual vinyl ether  
15 lipid units at either the  $R^1$  or  $R^2$  position, with the other position in the respective units being the hydrophilic headgroup moiety. Several vinyl ether lipid units may be crosslinked in this fashion by selecting a crosslinker with a plurality of crosslinking functional moieties, as for example, a polymer with an appropriate functionality. Suitable crosslinkers include, but are not limited to triethylenediamine,  $\alpha,\omega$ -  
20 polyethylene glycol,  $\alpha,\omega$ -polyethylenimine,  $\alpha,\omega$ -polyglycidol,  $\alpha,\omega$ -polyacrylic acid, polylysine, polyarginine, spermine, and spermidine.

The vinyl ether lipid compounds of the present invention can be synthesized in a variety of methods. One such method begins by protecting one hydroxyl group of 1,4-butanediol with a blocking reagent, such as *t*-butyldimethylsilylchloride, followed  
25 by oxidation of the second hydroxyl to provide a carboxyl group, as for example with potassium permanganate. An ester bond is then formed by a condensation reaction with the carboxy group and a hydroxy group on the desired hydrophobic tailgroup portion, as for example by reaction with cholesterol or the dioleoyl ester of glycerol in DMAP and EDCI. The ester bond is then converted to a vinyl ether bond through a  
30 phosphonyl intermediate, followed by reduction with a palladium/aluminum catalyst,



as for example, by reacting the ester with n-butyllithium and diisopropylamine, followed by reaction with chlorodiethylphosphate to produce the diethylphosphonyl-1-butene, and then reacting the phosphonyl butene intermediate with  
5     tertrakistriphenylphosphate palladium and triethylaluminum in methylene chloride to produce the racemic vinyl ether lipid. Lastly, the blocking group is removed to regenerate a hydroxyl group, which is then condensed with a free carboxy group on the hydrophilic headgroup to yield an amphiphilic lipid compound with a vinyl ether linked hydrophilic headgroup according to the present invention.

Alternatively, a simplified synthetic method to produce the vinyl ether lipid  
10     compounds of the present invention, which results in similar or better yields and fewer problematic waste products, is as follows:

2-Vinyl-1,3-dioxolane is reacted with an  $\omega$ -protected alkyllithium, such as 4'-*t*-butyldiphenylsilyl-2-(2'-butenyl)-1,2-dioxolane, to effect the vinyl addition of the alkyl group with the opening of the dioxolane ring, forming a vinyl ether group and a  
15     reactive oxide ion. Upon completion of the reaction, a weak acid, such as water, or a sulfonyl chloride such as mesyl or tosyl chloride, is added to yield the corresponding alcohol or sulfonate. Substitution of these groups with hydrophobic moieties, via ether, ester, carbamyl, or alkyl groups gives a protected hydrophobic vinyl ether intermediate. This intermediate is then reacted with a fluorous deprotecting agent, as  
20     for example, but without limitation, TBAF, hydrofluoric acid, or sodium fluoride. The unprotected intermediate is then reacted with a precursor of the desired hydrophilic headgroup having an active hydroxy, amino, sulfonate, or phosphate group to coupled the headgroup to the vinyl group to yield a vinyl ether lipid with the cleavable linkage in the aqueous region of the membrane interface.

25     In another aspect of the present invention, there are provided liposomes comprising at least two different species, or types of lipid compounds, at least one of which is an amphiphilic lipid compound having a vinyl ether linked hydrophilic headgroup as described above. Methods for forming lipid vesicles or liposomes, particularly those containing desirable agents such as therapeutic drugs and/or  
30     diagnostic indicators, are well known in the art. It is likewise known how to select



lipids to provide a general targeting of the liposome for specific tissue or cell types. The present invention provides for the modification for such liposomes or lipid vesicles to facilitate their interaction with biological membranes when the liposomes come in contact with the target tissues or membranes, primarily to allow the delivery  
5 of the liposome contents to the target tissue or across the target membrane.

In a preferred embodiment, liposomes are made to include at least one species of vinyl ether lipid compound of the present invention. In a preferred embodiment, the one or more vinyl ether lipid compounds of the present invention constitute between about 0.1% and about 20% of the molar lipid content of the liposomes. More  
10 preferably, the liposomes molar lipid content contains between about 1.0% and about 15% vinyl ether lipid compound. In one embodiment of the present invention the liposomes contain between about 3.0% and about 10% vinyl ether lipid on a molar basis of the lipid content. It is to be understood that the vinyl ether lipid concentrations may be the sum of one or more vinyl ether lipid compounds of the  
15 present invention as desired for a particular application.

By the controlling the selection of the specific vinyl ether lipid compound or compounds used in the liposome synthesis and their relative concentrations, as well as the selection of other lipids and targeting agents, etc., the skilled artisan can tailor construct liposomes of a given stability for circulation, and of a desired release rate  
20 profile or fusogenicity to suit a particular therapeutic or diagnostic indication.

By way of example, but without limitation, it is known that the lipid, DOPE, does not form vesicles, but rather exists in aqueous media in a hexagonal tubular array. When 1-3 mole percent CVEP is added, the lipid mix can form liposomes. About 3-5 mole percent CVEP:DOPE can be used to form liposomes of suitable stability for cell  
25 culture uses, whereas about 5-10 mole percent is preferred for in vivo applications. The skilled chemist will be able to select optimum liposome compositions to suit a given application.

Liposomes comprising one or more vinyl ether lipid compounds of the present invention and containing a desired therapeutic or diagnostic agent encapsulated within  
30 the liposome may be used to deliver the agent to a desired target tissue or across a

biological membrane, as for example delivering the agent to the interior of a living cell within a target tissue. Target tissues or cells are contacted with liposomes encapsulating a desired therapeutic agent or diagnostic agent according to the present invention under acidic or oxidative conditions effective to cleave the vinyl ether bond of the vinyl ether lipids, thereby dissociating the hydrophilic headgroups from the hydrophobic tailgroup portions of the molecules. The dissociation causes a destabilization of the liposome, as for example by a phase transition from the lamellar phase to a hexagonal phase, thereby causing leakage of the liposomal contents into the tissue or cellular site, or a permeabilization of or fusion with a target membrane resulting in releasing the liposomal contents into the cellular compartment across the membrane.

In one embodiment, the liposomes encapsulating a therapeutic or diagnostic agent are designed to be endocytosed by the target cell population. Upon uptake, the endocytic vesicle is naturally acidified, which causes cleavage of the vinyl ether bond of the vinyl ether lipids, dissociating the hydrophilic headgroups therefrom. The dissociation destabilizes the liposome, inducing fusion of the liposomal membrane with the cellular endocytic vesicle membrane resulting in the release of the liposomal contents, including the therapeutic or diagnostic agent, into the cytoplasm of the cell.

In another embodiment, liposomes encapsulating a therapeutic or diagnostic agent are designed to accumulate in a target tissue having an acidic interstitial environment, as for example certain tumor tissues or ischemic tissues. Upon reaching the target tissue, the acidic conditions cause cleavage of the vinyl ether bonds of the vinyl ether lipids, dissociating the hydrophilic headgroups therefrom. The dissociation destabilizes the liposome, inducing the breakdown of the liposome to release the liposomal contents, including the therapeutic or diagnostic agent, into the interstitial fluid of the tissue. Alternatively or in addition, the destabilization may induce fusion of the liposomal membrane with the cellular membrane resulting in the release of the liposomal contents into the cytoplasm of the cells in the target tissue.

In yet another embodiment, the liposomes encapsulating a therapeutic or diagnostic agent also contain an oxidative sensitizer agent, as for example,

bacteriochlorophyll *a*, or an agent that can be activated to induce acidification of the liposome (an acidification agent). The liposomes are designed to accumulate in a predetermined tissue type. When the liposomes reach the target tissue, the oxidative sensitizing agent is excited or the acidifying agent is activated, thereby causing the cleavage of the vinyl ether lipids, dissociating the hydrophilic headgroups therefrom. The dissociation destabilizes the liposome, inducing the breakdown of the liposome to release the liposomal contents, including the therapeutic or diagnostic agent, into the interstitial fluid of the tissue. Alternatively or in addition, the destabilization may induce fusion of the liposomal membrane with the cellular membrane resulting in the release of the liposomal contents into the cytoplasm of the cells in the target tissue.

The following are examples of specific embodiments of the present invention and are illustrative of its principles. They are not to be considered restrictive, but merely representative of the broader invention disclosed.

#### 15 **Example 1. Synthesis of CVEP**

**(See Figures 1 & 2).**

**4- *O*-(*t*-butyldimethylsilyl)-butane-1-ol (1).** A modified procedure using THF instead of DMF as solvent and slow addition of the silyl chloride reagent were used [2]. *t*-Butyldimethylsilyl chloride (8.57g, 56.9 mmol) in dry THF (25 ml) was added dripwise to a solution of 1, 4-butanediol (20.05g, 222mmol; dried *in vacuo* overnight) and imidazole (4.8g, 70.5mmol) in THF (100ml) at 0°C over a ~20 min period. The reaction was stirred for 1hr (turned cloudy after 10 min), warmed to room temperature, and ether (300 ml) added. The solution was then washed with sat. NH<sub>4</sub>Cl (2 x 200 ml) and sat. NaCl (1x 200 ml). The ether layer was dried over MgSO<sub>4</sub>, filtered, evaporated and dried *in vacuo* yielding 10.8g of a pale yellow oil. NMR analysis indicated that the product was sufficiently pure to utilize in the subsequent step without further purification. Isolated yield: 93%. TLC: 4:1 hexane:ether, KMnO<sub>4</sub> stain; 0.85, 0.35 (product), 0.0; spots at 0.85 & 0 were faint. <sup>1</sup>HNMR (ppm, 200 MHz, CDCl<sub>3</sub>): 0.05 (t, 6H), 0.85 (s, 9H), 1.60 (m, 4H), 2.60 (s, 1H), 3.65 (q, 4H).

4- O-(*t*-Butyldimethylsilyl) butanoic acid (2) [3]. Potassium permanganate (3.2g, 20.2 mmol) was dissolved in water (50 ml), stirred vigorously for 10 min, and cooled to 0°C. A benzene solution (40 ml) of **1** (1.98g, 9.7 mmol) and TOAB (812 mg, 1.5 mmol) was added dropwise via addition funnel over 20 min. The solution was then warmed to room temperature and stirred for 3 h. The remaining potassium permanganate was quenched with sodium bisulfite, producing a two phase mixture with a colorless organic layer. Acetic acid (50 ml, 50%) and benzene (20 ml) were added and the solution extracted. The benzene layer was washed with sat. NaCl (50 ml), then dried over MgSO<sub>4</sub>, filtered, evaporated, and dried *in vacuo*. The remaining TOAB was removed via elution through a small silica plug with 2:1 hexane:ether. (Subsequent experiments indicated that tetrabutylammonium bromide works just as well as phase transfer catalyst and is easier to remove in this step). A clear oil (1.65g, 78% yield) was recovered. TLC: 1:1 hexane:ether, Bromphenol blue stain, 0.65. <sup>1</sup>H NMR (ppm, 200 MHz, CDCl<sub>3</sub>): 0.05 (s, 6H), 0.85 (s, 9H), 1.83 (p, J=7Hz, 2H), 2.44 t, J=9Hz, 2H), 3.65 (t, J=7Hz, 2H), 11.57 (bs, 1H). <sup>13</sup>C NMR (ppm, 60 MHz CDCl<sub>3</sub>): 18.2, 25.8, 27.8, 31, 62.

Cholesteryl-4-O-(*t*-butyldimethylsilyl) butanoate (3). Cholesterol (609 mg, 1.58 mmol), **2** (325 mg, 1.49 mmol), and DMAP (20 mg, 0.14 mmol) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (15 ml) and the solution cooled to 0°C. EDCI (284 mg, 1.49 mmol) was added, the mixture warmed to room temperature and stirred for up to 10 days (TLC monitoring suggests that 2-3 days is sufficient). The reaction mixture was poured into H<sub>2</sub>O (75 ml) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 75 ml). The combined CH<sub>2</sub>Cl<sub>2</sub> layers were dried over MgSO<sub>4</sub>, filtered, evaporated, and dried *in vacuo*. The crude product was purified via silica gel chromatography (230-400 mesh, 9:1 hexane: ether, 1.5 cm diameter x 5 cm height column). A white solid (780 mg) was recovered in 90% yield. TLC: 2:1 hexane:ether, acid char (cholesterol & its derivatives initially stain purple, but turn brown with time), 0.52 (purple/brown, product), 0.13 (purple/brown, cholesterol starting material). <sup>1</sup>H NMR (ppm, 200 MHz, CDCl<sub>3</sub>): 0.05 (s, 6H), 0.65 (s 3H), 0.8-2.05 (m, 47H), 2.25-2.4 (m, 4H), 3.65 (t, J=7Hz, 2H), 4.6 (m, 1H), 5.35 (d,

$J=5\text{Hz}$ ,  $1\text{H}$ ).  $^{13}\text{C}$  NMR (ppm,  $60\text{Hz}$ ,  $\text{CDCl}_3$ ): 19-75 multiple peaks, 123, 140.5, 174.

MS (CI,  $70\text{ eV}$ ):  $m/z$  587 ( $\text{M} + \text{H}$ ).

4-*O*-(*t*-Butyldimethylsilyl)-1-*O*-(cholesteryl)-1-*O*-(1-diethylphosphonyl)-1butene (4) [4]. *n*-Butyllithium (795  $\mu\text{l}$ , 1.94 mmol, 2.4M in hexane) was added dropwise via syringe to diisopropylamine (453  $\mu\text{l}$ , 3.23 mmol) in THF (250  $\mu\text{l}$ ,) at -78°C and the solution stirred for 30 min. Cholesteryl-4-*O*-(*t*-butyldimethylsilyl) butanoate (758 mg, 1.29 mmol) in THF (3 ml) was then slowly added dropwise via syringe. The solution was stirred for 1 h followed by the addition of chlorodiethylphosphate (373  $\mu\text{l}$ , 2.58 mmol) in HMPA (4.9 ml) in 3 aliquots. The solution turned orange/brown and froze. It was thawed enough to resume stirring, then returned to -78°C for 10 min. The reaction was then warmed to room temperature and stirred for another 1 h. Ether (50 ml) was added and the reaction mixture filtered through a small silica plug. The solvents were then evaporated and the oil redissolved in ether (75 ml) and washed with 5%  $\text{NaHCO}_3$  (3 x 75 ml). The ether layer was dried over  $\text{MgSO}_4$ , filtered, evaporated, and dried *in vacuo*. The crude product was purified via silica gel flash chromatography (230-400 mesh, 6:1 hexane:ether, 2 cm diameter x 16 cm height). Solid product was recovered after evaporation (750 mg, 81% yield). The product was immediately used in the subsequent step without further purification or characterization. TLC: 2:1 hexane:ether,  $\text{I}_2$  stain, 0.74 (faint, starting material), 0.35 (dark, product), 0.1 (dark, HMPA).

4-*O*-(*t*-Butyldimethylsilyl)-1-*O*-(cholesteryl)-1butene (5).

Tetrakis(triphenylphosphine) palladium (50 mg, 43.3  $\mu\text{mol}$ s) and 4 (960 mg, 1.33 mmol) were added to  $\text{CH}_2\text{Cl}_2$  (8 ml) and cooled to 0°C. Triethylaluminum (2.33 ml, 2.33 mmol; 1.0 M in hexane) was then added dropwise via syringe. The solution was stirred at 0°C for 1 h before warming to room temperature and stirring for an additional 3 h. The crude mixture was purified via silica gel flash chromatography (230-400 mesh, 8:1 hexane:ether, 2 cm diameter x 12 cm height) yielding a mixture of product and cholesteryl-4-*O*-(*t*-butyldimethylsilyl) butanoate. This mixture was again separated via silica gel flash chromatography (230-400 mesh, 14:1 hexane:ether, 2 cm



diameter x 25 cm height). A white solid was recovered (160 mg, 21% yield) as a 75:25 cis:trans mixture. TLC: 8:1 hexane:ether, acid char, 0.8 (dark, product), 0.75 (dark, ester), 0.15 (dark, vinyl phosphate starting material). <sup>1</sup>H NMR (ppm, 200 MHz, CDCl<sub>3</sub>): 0.5 (s, 6H), 0.65 (s, 3H), 0.8-2.05 (m, 47H), 2.25-2.4 (m, 3H), 3.45 (m, 1H),  
5 3.6 (t, J=12 Hz, 2H), 4.4 (dt, J<sub>1</sub>=6Hz, J<sub>2</sub>=9Hz, .75H), 4.85 (dt, J<sub>1</sub>=14Hz, J<sub>2</sub>=9Hz, .25H), 5.35 (m, 1H), 6.05 (dt, J<sub>1</sub>=6Hz, J<sub>2</sub>=3Hz, .75H), 6.15 (dt, J<sub>1</sub>=14Hz, J<sub>2</sub>=2Hz, .3H).

4-*o*-(Cholesteryl)-3Z-buten-1-ol (6). TBAF (210 μl, 210 mmol, 1.0 M in THF) and 1.0 ml TBAOH were added via syringe to 5 (40 mg, 70 μmol) in THF (3 ml). The  
10 reaction was run for 12 h then filtered through a small silica plug with ether, the solvent evaporated, and the mixture purified by silica gel flash chromatography (230-400) mesh, 8:1 hexane:ether, 1.5 cm diameter x 15 cm height) to give 4-cholestoxy-3Z-buten-1-ol (29 mg, 91% yield) and 4-cholestoxy-3E-buten-1-ol (1.5 mg, 4% yield). TLC: 2:1 hexane:ether, acid char, 0.63 (faint, starting material), 0.18 (dark, cis  
15 product), 0.14 (dark, trans product). **6cis:** <sup>1</sup>H NMR (ppm, 200 MHz, C<sub>6</sub>D<sub>6</sub>): 0.65 (s, 3H), 0.8-2.05 (m, 47H), 2.3-2.5 (m, 3H), 3.35 (m, 1H), 3.6 (t, J=12Hz, 2H), 4.4 (dt, J<sub>1</sub>=6Hz, J<sub>2</sub>=9Hz, 1H), 5.35 (m, 1H), 6.05 (dt, J<sub>1</sub>=6Hz, J<sub>2</sub>=3Hz, 1H). **6trans:** <sup>1</sup>H NMR (ppm, 200 MHz, C<sub>6</sub>D<sub>6</sub>): 0.65 (s, 3H), 0.8-2.05 (m, 50H), 2.4-2.5 (m, 2H), 3.35 (t, J=12Hz, 2H), 3.5 (m, 1H), 4.95 (dt, J<sub>1</sub>=14Hz, J<sub>2</sub>=9Hz, 1H), 5.35 (m, 1H), 6.15 (dt,  
20 J<sub>1</sub>=14Hz, J<sub>2</sub>=2Hz, 1H). MS (CI): m/z 457 (M + H).

4-*o*-Cholesteryl-(3Z-buten-1-yl)-polyethylene [125] glycolate (CVEP, 7). 4-Cholestoxy-3Z-buten-1-ol (28 mg, 61.3 μmol), M-PEG-acid (MW 5000, 278 mg, 55.7 μmol, Shearwater Polymers), DCC (13.77 mg, 66.9 μmol), and DMAP (10 mg, 18.8 μmol) were added to CH<sub>2</sub>Cl<sub>2</sub> (2 ml) and stirred for 4 d. The dicyclohexylurea  
25 sideproduct crystals were then removed by filtration and the solvent concentrated to 2 ml. The concentrate was then dripped into cold ether and the ether solutions centrifuged at 3500g for 10 min. The ether was then decanted and the pellet washed with fresh ether. This process was repeated 5 more times before the pellet was dissolved in CH<sub>2</sub>Cl<sub>2</sub>, evaporated to a dry film, dissolved in 2 ml 18 MΩ Millipore H<sub>2</sub>O  
30 and lyophilized to give 215 mg (71% yield) of PEG containing product. <sup>1</sup>H NMR

indicates the presence of vinyl ether (6.1 ppm), PEG (3.5 ppm), and cholesterol (0.7-2.5 ppm) resonances in approximately the correct ratios.

rac-2,2-Dimethyl-1,3-dioxolane-4-*t*-butyldiphenylsilyl methanol (8) [5]. (S)-(+)-2,2 Dimethyl-1, 3-dioxolane-4-methanol (26.5 g, 200.5 mmol) and imidazole (21.1g, 309.9 mmol) were dissolved in THF (250 ml). *t*-Butyldimethylsilyl chloride (61.0g, 222.6 mmol) was added dropwise via addition funnel over 15 min. A white precipitate formed with the production of a mild exotherm. The reaction was stirred for 2 h then divided into two 175 ml portions. Each portion was added to ether (700 ml) and extracted with H<sub>2</sub>O (3 x 600 ml). The combined ether layers were dried over MgSO<sub>4</sub>, filtered, evaporated, and dried *in vacuo* to give a faint yellow oil (77.1g, 100% yield). Although this material contained traces of silanol sideproduct and imidazole, it was judged to be sufficiently pure for direct use in the subsequent reaction. TLC: 1:1 hexane:ether, UV, 0.6 (dark, product), 0.53 (faint, SiOH). <sup>1</sup>H NMR (ppm, 200 MHz, CDCl<sub>3</sub>), 1.1 (s, 9H), 1.38 (s, 3H), 1.42 (s, 3H), 3.75 (m, 2H), 3.86 (m, 1H), 4.1 (m, 1H), 4.22 (m, 1H), 7.43 (m, 6H), 7.70 (m 4H).

rac-3-*t*-Butyldiphenylsilylpropanetriol (9) [6]. 8 (13.0 g, 35.1 mmol) was dissolved in ethanol (100 ml), followed by the addition of concentrated HCl (7 ml) and H<sub>2</sub>O (10 ml). The reaction was run for 12 min before quenching with 4 M NaOH (100 ml) and product extraction with ether (3x 100ml). The ether layer was then dried over MgSO<sub>4</sub>, filtered, evaporated, and dried *in vacuo*. The crude reaction mixture was then purified via silica gel chromatography (60-200 mesh, 2 cm diameter x 5 cm height) using 1:1 hexane:ether to elute the starting material (4.8 g), followed by a step gradient of ethyl acetate to elute the product (7.1 g, 61% yield; 97% yield based on converted starting material). TLC: 1:1 hexane:ether, UV KMnO<sub>4</sub>, 0.65 (faint, UV only, starting material), 0.16 (dark, UV and KMnO<sub>4</sub>, product). <sup>1</sup>H NMR (ppm, 200 MHz, CDCl<sub>3</sub>): 1.1 (s, 9H), 2.05 (bs, 2H), 3.6-3.9 (m, 5H), 7.43 (m, 6H), 7.70 (m 4H).

rac-1,2-Dioleoyl-3-*t*-butyldiphenylsilylglycerol (10) [7.8]. Sodium hydride (1.0041g, 25 mmol, 60% dispersion in mineral oil) was washed with THF (3 x 10 ml) prior to the addition of THF (20 ml) and 9 (1.9442g, 5.9 mmol). After gas evolution ceased (~10 min) oleyl triflate was added (5.03g, 12.6 mmol) and the reaction stirred



until complete within 1 h. The solution was evaporated to dryness, redissolved in hexane, and filtered through a small silica plug with hexane. The hexane eluent was evaporated and dried *in vacuo* to give a clear viscous oil (4.26 g, 87% yield). TLC: 2:1 hexane:ethyl acetate, UV & acid char, 0.75 (dark, UV product). <sup>1</sup>H NMR (ppm, 200 MHz, CDCl<sub>3</sub>): 0.90(t, J=6Hz, 6H), 1.05 (s, 9H), 1.3 (bs, 44H), 1.55 (m, 4H), 2.0 (m, 8H), 3.3-3.75 (m, 9H), 5.35 (t, J=10Hz, 4H), 7.43 (m, 6H), 7.70 (m 4H).

rac-1,2-Dioleoylglycerol (11). TBAF (7.3 ml, 7.2 mmol, 1.0M in THF) was added to a solution of **10** (2.043g, 25 mmol) in THF (35 ml). TBAOH (0.1 ml) was then added and the reaction run for 10 h. The solution was then evaporated and the crude product mixture purified via silica gel chromatography (60-200 mesh, 10:1 hexane:ether, 3 cm diameter x 20 cm height) to give 1.2g of a viscous oil (81% yield). TLC: 6:1 hexane:ether, UV & acid char, 0.3 (dark, UV only, SiOH), 0.22 (dark, acid char only, product). <sup>1</sup>H NMR (ppm, 200 MHz, CDCl<sub>3</sub>): 0.90 (t, J=6Hz, 6H), 1.3 (bs, 44H), 1.58 (m, 4H), 2.0 (m, 8H), 2.2 (t, J=5Hz, 1H), 3.4-3.8 (m, 9H), 5.35 (t, J=5Hz, 4H).

rac-1,2-Dioleoyl-3-(4'-*t*-butyldiphenylsiloxybutanoate)glycerol (12). 1,2-Dioleoyl-rac-glycerol (2.23g, 3.76 mmol), **2** (0.781g, 3.58 mmol), and DMAP (20 mg, 0.14 mmol) were dissolved in CH<sub>2</sub>Cl<sub>2</sub> (15 ml). EDCI (1.03g, 5.37 mmol) was then added and the reaction stirred for 2 d. The product mixture was poured into H<sub>2</sub>O (50 ml) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 x 50 ml). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, evaporated, and dried *in vacuo*. The crude product was purified via silica gel flash chromatography (230-400 mesh, 8:1 hexane:ether, 2 cm diameter x 25 cm height) to give 1.05 g product (53% yield based on consumed starting material) and 751 mg starting material. TLC: 2:1 hexane:ether, I<sub>2</sub> stain, 0.71 (dark, product), 0.51 (impurity), 0.41 (dark, starting material). <sup>1</sup>H NMR (ppm, 200 MHz, CDCl<sub>3</sub>): 0.05 (s, 6H), 0.90 (m, 15H), 1.3 (bs, 44H), 1.55(m, 4H), 1.82 (p, J=10Hz, 2H), 2.0 (m, 8H), 2.4 (t, J=10Hz, 2H), 3.35-3.65 (m, 9H), 4.0-4.13 (dd, J=8Hz, H=6Hz, 1H), 4.17-4.27 (dd, J=9Hz, J=6Hz, 1H), 5.32 (t, J=5Hz, 4H). MS (CI): m/z 793 (M + H).

Vinyl phosphate of rac-1,2-dioleoyl-3-(4'-*t*-butyldiphenylsiloxybutanoate)-glycerol (13). *n*BuLi (635  $\mu$ l, 1.55 mmol) was added dropwise via syringe to a

solution of diisopropyl amine (362  $\mu$ l, 2.58 mmol) in THF (200  $\mu$ l) at - 78°C. The mixture was stirred for 30 min then a THF solution of **12** (820 mg, 1.03 mmol) was added dropwise via syringe and stirred for 1 h. Diethylchlorophosphate (298  $\mu$ l, 2.06 mmol) in HMPA (10.5 ml) was then added in 3 aliquots, after which the reaction mixture turned orange and froze. The mixture was then warmed to room temperature and stirred 1 h before filtering through a small silica plug with anhydrous ether. The filtrate was evaporated, redissolved in ether (200 ml), and extracted with 5% NaHCO<sub>3</sub> (2 x 200 ml). The ether layer was then dried over MgSO<sub>4</sub>, filtered, evaporated, and dried *in vacuo*. The crude mixture was purified via silica gel chromatography (230-400 mesh, 3.5 cm diameter x 12 cm height, 8:1 hexane:ether to elute starting material, 4:1 hexane:ether to elute the product) to give 250 mg of product (27% yield). TLC: 2:1 hexane:ether, I<sub>2</sub> stain, 0.75 (dark, product), 0.33 (impurity), 0.23 (dark, product).

rac-1,2 Dioleyl-3-(4'-*t*-butyldiphenylsiloxyl-1'-butenyl)-glycerol (**14**).

Tetrakis(triphenyl-phosphine) palladium (40 mg, 34.6  $\mu$ mol) and **13** (250 mg, 269  $\mu$ mol) were dissolved in 3 ml CH<sub>2</sub>Cl<sub>2</sub> and cooled to 0°C. Triethylaluminum (471  $\mu$ l, 471  $\mu$ mol, 1M hexane solution) was added dropwise via syringe. The reaction was warmed to room temperature and stirred for 4h. The product mixture was filtered through a small silica plug with anhydrous ether, the filtrate evaporated, and dried *in vacuo*. The crude mixture was purified via silica gel chromatography (60-200 mesh, 8:1 hexane:ether, 2 cm diameter x 10 cm height). Fractions containing the product and ester (fastest eluting material) were combined, evaporated, and rechromatographed (230-400 mesh silica gel, 14:1 hexane:ether, 2 cm diameter x 27 cm height). The product (25 mg, 12% yield) and **12** (100 mg) were recovered. TLC: 14:1 hexane:ether, I<sub>2</sub> stain, 0.75 (dark, **14**), 0.50 (medium, **12**). <sup>1</sup>H NMR (ppm, 200 MHz, CDCl<sub>3</sub>): 0.05 (s, 6H), 0.85 (m, 15H), 1.30 (m, 44H), 1.58 (m, 4H), 1.82 (p, J= 7Hz, 2H), 2.0 (m, 8H), 2.2-2.4 (m 2H), 3.35-3.85 (m, 9H), 4.05 (t, J=8Hz, 1H), 4.35 (dt, J<sub>1</sub>=6Hz, J<sub>2</sub>=9Hz, 0.65H), 4.72 (dt, J<sub>1</sub>=12Hz, J<sub>2</sub>=9Hz, 0.35H), 5.35 (t, J=5Hz, 4H), 5.98 (dt, J<sub>1</sub>=6Hz, J<sub>2</sub>=3Hz, 0.65H), 6.28 (dt, J<sub>1</sub>=14Hz, J<sub>2</sub>=2Hz, 0.35H).

rac-1,2-Dioleyl-3-(4'-hydroxy-1'-butenyl)-glycerol (**15**). TBAF (50  $\mu$ l, 80

$\mu$ mol, 1.0M in THF), and TBAOH (0.5 ml) were added to **14** (25 mg, 32.2  $\mu$ mol) in

THF (4 ml) and stirred for 24 h. The mixture was then filtered through a small silica gel plug with ether, the filtrate evaporated, and the residue dried *in vacuo*. The crude mixture was separated via a silica gel chromatography (Pasteur pipette minicolumn 0.5 cm diameter x 4 cm height, 8:1 hexane:ether) to give pure **15cis** (9 mg) and 2 mg of a 86:14 **15 trans:15cis** mixture as colorless oils. Overall yield: 52%. TLC 14:1 hexane:ether, I<sub>2</sub> stain, 0.68 (faint, **14**) 0.33 (impurity), 0.28 (dark, **15cis**), 0.24 (medium, **15trans**). **15cis** <sup>1</sup>H NMR (ppm, 200 MHz, C<sub>6</sub>D<sub>6</sub>): 0.85 (m, 6H), 1.30 (m, 44H), 1.58 (m, 4H), 2.1 (m, 8H), 2.4 (m 2H), 3.25-3.4 (m, 2H), 3.4-3.63 (m, 7H), 3.7-3.83 (m, 2H), 4.35 (dt, J<sub>1</sub>=6Hz, J<sub>2</sub>=9Hz, 1H), 5.35(t, J=5Hz, 4H), 6.0 (dt, J<sub>1</sub>=6Hz, J<sub>2</sub>=3Hz, 1H). **15trans** <sup>1</sup>H NMR (ppm, 200 MHz, C<sub>6</sub>D<sub>6</sub>): 0.85 (m, 6H), 1.30 (m, 44H), 1.58 (m, 4H), 1.8 (m 2H), 2.1 (m, 8H), 3.25-3.4 (m, 2H), 3.4-3.63 (m, 7H), 3.7-3.83 (m, 2H), 4.72 (dt, J<sub>1</sub>=12Hz, J<sub>2</sub>=9Hz, 1H), 5.35 (t, J=5Hz, 4H), 6.30 (dt, J<sub>1</sub>=14Hz, J<sub>2</sub>=2Hz, 1H).

rac-1,2-Dioleoyl-3-(4'-hydroxy-1'-butenyl)-glyceryl polyethylene [125]

glycolate (DVEP, 16). M-PEG-acid (MW 5000, 62 mg, 12.4 μmol, Shearwater Polymers), **15cis** (9 mg, 13.6 μmol), DCC (3 mg, 14.6 μmol), and DMAP (1 mg, 8.2 mmol) were added to CH<sub>2</sub>Cl<sub>2</sub> (2 ml) and stirred for 3 d. At the end of the reaction, the crystalline dicyclohexylurea side product was removed by filtration and the solvent concentrated to 2 ml. The concentrate was then dripped into cold ether and the ether solution centrifuged at 3500g for 10 min. The ether was then decanted and the pellet washed with fresh ether; this process was repeated five more times. The pellet was then dissolved in CH<sub>2</sub>Cl<sub>2</sub> and evaporated to a dry film.

CVE-DC, 17. 2,2'-Dipyridyl carbonate, **6**, and triethylamine were stirred for 3 d in 10 ml CH<sub>2</sub>Cl<sub>2</sub>. The reaction mixture was extracted with 25 ml NaHCO<sub>3</sub>, followed by 25 ml saturated NaCl. The CH<sub>2</sub>Cl<sub>2</sub> layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The resulting oil was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 ml). 1,5-Diphalamidyldiethylenetriamine (315 mg, 0.868 mmol) was added and the reaction stirred for 3 d. The solution was evaporated and the crude mixture purified via flash chromatography (3:2 hexane:ether), yielding 350 mg of a clear oil (69% yield). This product was dissolved in 60 ml methanol, hydrazine hydrate added, and the reaction

mixture stirred for 2 d. The solution was then evaporated, yielding an off white precipitate. Chloroform (50 ml) was added and the precipitate side product removed via filtration. The filtrate was evaporated and dried *in vacuo* overnight yielding a faint yellow oil.

- 5            DVE-DC, 18. This derivative was prepared in the same manner as for 17, except that 15 was used in the 2,2'-dipyridyl carbonate coupling reaction.

**Example 2. Methoxy-, Furanyl-, Thiophen-, and 4-Methoxyphenyl-Derivatives of CVEP.**

- 10            Derivatives of CVEP having methoxy, furanyl, thiophen, or 4-methoxyphenyl substitution on the vinyl moiety, gem to the ether oxygen are prepared via the 2-X-2-vinyl-1,3-dioxolane route, where X = methoxy, furanyl, thiophen, or 4-methoxyphenyl. The synthesis of these materials begins with the formation of the corresponding 1-X-propenone in good yields using a Mannich coupling and Hoffman elimination scheme. (See V. J. Gutzmann, P. Messinger, *Arch. Pharm.* 1995, vol. 328, 15 pg. 523-525, or P. Messinger, *Arch. Pharm.* 1973, vol. 306, pg. 603-610.) Tin-catalyzed acetalization with ethylene glycol gives the 2-X-2-vinyl-1,3-dioxolane precursor which is subsequently reacted under Barbier conditions (adding a mixture of the alkyl chloride and dioxolane compounds dropwise to the lithium compound in THF at 0-20°C with stirring) with 2-oxo-2-chloro-1,3,2-dioxaphospholane. These 20 species are then coupled to a selected hydrophobic segment using a chloroalkane derivative (RCl), and the dioxaphospholane rings are then opened with trimethylamine to generate an electron-rich vinyl ether product bearing a phosphonocholine headgroup (i.e.  $\text{Me}_3\text{N}^+-\text{CH}_2\text{CH}_2-\text{OPO}^-(\text{O})\text{CH}_2\text{CH}=\text{CXOR}$ ).

25            **Example 3. Alternative synthesis of CVEP.**

4'-*t*-Butyldiphenylsilyl-2-(2'-butenyl)-1,3-dioxolane was reduced with lithium. Aqueous workup then produced 1-(2'-hydroxyethoxy)-4-*t*-butyldiphenylsilyl-1-buten-4-ol in ~60% yield. Alkylation of this intermediate using sodium hydride/cholesteryl chloride, followed by fluoros ion mediated silyl deprotection and EDCI-mediated

coupling  $\omega$ -methoxypoly(ethyleneglycol), gave the hydroxyethyl derivative of CVEP in moderate yield.

**Example 4. Liposome Vesicle Preparation.**

5 DOPE and the labile PEG lipid were co-dissolved in chloroform that had been prefiltered through a 2.53 cm plug of anhydrous sodium carbonate to remove traces of acid and water from the solvent. This solution was evaporated under a gentle stream of N<sub>2</sub> and further dried under vacuum (<200  $\mu$ , 4 h). Vesicles were formed by hydrating the lipid film in the presence of 50 mM calcein using five LN<sub>2</sub> freeze-thaw-  
10 vortex cycles. This suspension was then extruded at 50°C through two 100nm track-etch polycarbonate membrane filters [9]. Extraliposomal calcein was removed using a single pass through a 40 cm Sephadex G-50 gel column equilibrated with 150 mM NaCl. The fraction eluting at the void volume was collected and stored at 8°C until use. Light-sensitive vesicles were prepared in the same manner, except that  
15 bacteriochlorophyll a (Bchl) was codissolved in the chloroform lipid solution. Other agents or mixtures of agents, such as therapeutic compounds or diagnostic agents, are substituted for calcein in the above protocol resulting in liposomal encapsulation of the substituted agent.

**Example 5. Triggered Release Assay.**

20 Vesicle release of the liposomes made in example 4 above, was monitored at 37°C as a function of time using the calcein fluorescence dequenching assay [10]. Acid-triggered release was initiated by dilution of the vesicles into an acidic buffer solution as described by Gerasimov et al [10]. Light-triggered release was promoted by aerobic illumination (800 nm, 1 W) of a continuously stirred 1 cm quartz cuvette  
25 with a SDL 820 diode laser coupled to an optical fiber [11]. The fiber was mounted perpendicular to the cuvette surface to produce a spot of ~3 mm diameter. Both triggering methods were conducted either in the absence or presence of ten-fold excess of egg phosphatidylcholine (EPC) vesicles as a membrane "sink".

**Results**



**Acid-triggered Release.** The calcein release properties of 98:2 and 96:4 DOPE:CVEP vesicles at pH 7.4 and 4.5, both in the presence and absence of sink EPC vesicles, are shown in **Figure 3**. These data suggest the following trends: (i) very little contents leakage is observed at neutral pH, regardless of whether sink EPC is present or not, (ii) calcein leakage occurs in the presence of sink EPC at pH 4.5, (iii) very little contents leakage is observed at pH 4.5 in the absence of sink EPC, and (iv) the rate of calcein leakage under sink conditions at pH 4.5 is dependent upon the vesicle CVEP content, with lower loadings producing more rapid release rates. The last observation is further illustrated in **Figure 4**, where DOPE:CVEP vesicles with varying CVEP content were prepared and analyzed for calcein release rate pH 2.0. A strong dependence on release rates was observed, with the half life for release (i.e.  $t_{50\% \text{ release}}$ ) measured as 45, 90, 120, and 155 min for 0.5, 2, 3, and 4% CVEP loadings, respectively. This data clearly indicates that the release rate profiles can be “tuned” by controlling the DOPE:CVEP ratio in the vesicle formulation.

The release rate properties of 98:2 DOPE:DVEP vesicles (**Figure 5**) demonstrates that DVEP shares some of the characteristics of DOPE:DVEP vesicles, namely the lack of leakage at pH 7.4, regardless of whether sink EPC is present or not. Two properties of this compound differ from the CVEP case: (i) the DVEP release rates are much faster at pH 4.5 than for CVEP at identical loadings (i.e.  $t_{50\% \text{ release}}=23$  and 220 min for DVEP and CVEP, respectively) and (ii) significant release occurs in the absence of sink EPC at pH 4.5 in this system ( $t_{50\% \text{ release}} \approx 3 \text{ h}$ ). These results suggest that this compound will be most useful in applications requiring rapid triggering, even in the absence of sink membrane material.

**Oxidative Release.** The release characteristics of 98:2 DOPE:CVEP:Bchl<sub>a</sub> (pH 7.4) under photooxidative conditions is shown in **Figure 6**. Irradiation of these vesicles lead to slow release in the absence of sink EPC, however, the observed release rate increased significantly when sink lipid was present. Background (dark) calcein leakage from the vesicles was not significant, even in the presence of sink EPC.

**Cytoplasmic Delivery.** DOPE:CVEP/calcein vesicles using folate as a targeting ligand (DSPE-PEG3350-folate) initially revealed punctuated fluorescence,

followed by diffuse cytoplasmic fluorescence. This was indicative of vesicle escape of calcein within the early endosome, which subsequently lead to endosomal escape at longer incubation times. Results from preliminary *in vitro* studies suggest that this may occur via vesicle-endosome membrane fusion.

- 5     **Conclusions:** The novel amphiphilic compounds shown in Series I-III, bearing hydrophilic headgroups that are linked to a hydrophobic membrane anchor via a water-soluble vinyl ether substituent, have been synthesized and their efficacy in acid- or oxidatively-activated release has demonstrated.

10     **Example 6. Comparative cleavage rates for CVEP and BVEP.**

BVEP, having two vinyl ether linkages, each bonding a hydrophobic tailgroup to a glycerol moiety, which in turn is bonded through an ester linkage to a polyethylene glycol hydrophilic headgroup is synthesized by known methods. See J.A. Boomer & D.H. Thompson, Chem. Phys. Lipids (1999) vol. 99, pg. 145-153.

- 15     Rates of cleavage by acid hydrolysis and oxidation are measured in a comparative study for CVEP and BVEP as follows:

20     **Acid hydrolysis of CVEP and BVEP.** Micellar solutions of the vinyl ether lipids are hydrolyzed at 37°C, pH 4.5 in 20 mM citrate buffered saline (150 mM). Samples of the hydrolysis mixture are periodically withdrawn and analyzed by HPLC (C<sub>18</sub> column, MeOH-H<sub>2</sub>O gradient, 1.5 ml/min). The disappearance of CVEP (retention time = 34.7 min) due to acid-catalyzed hydrolysis is faster than the disappearance of BVEP (retention time = 39-40 min) under the same experimental conditions.

25     **Photooxidation of CVEP and BVEP.** Micellar solutions of the vinyl ether lipids are photooxidized at 37°C in the presence of bacteriochlorophyll *a* and air-saturated buffer (20 mM HEPES, 150 mM NaCl, pH 7.4). Samples of the photolysis mixture are periodically withdrawn and analyzed by HPLC (C<sub>18</sub> column, MeOH-H<sub>2</sub>O gradient, 1.5 ml/min). The disappearance of CVEP (retention time = 34.7 min) due to photolysis is faster than the disappearance of BVEP (retention time = 39-40 min) under the same experimental conditions.



While the invention has been described in detail in the foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only the preferred embodiments have been described and that all changes and modifications that come within the spirit of the invention are desired to be  
5 protected.

We claim:


1. An amphiphilic lipid compound having an acid or oxidatively labile vinyl ether linked hydrophilic headgroup.

5 2. The amphiphilic lipid compound of claim 1 wherein said vinyl ether linkage consists of two carbon atoms bonded by a carbon-carbon double bond and an ether oxygen bonded to one of said carbons; and wherein said hydrophilic headgroup is bonded to one of said double bonded carbon atoms and said ether oxygen is bonded to the other said double bonded carbon atoms.

10

3. The amphiphilic lipid compound of claim 2 further comprising one or more hydrophobic tailgroups each bonded either directly to the ether oxygen, or bonded through an ether or ester linkage to a polyalcohol which is bonded directly to the ether oxygen, each of said one or more hydrophobic tailgroups being independently selected  
15 from the group consisting of sterol, fatty acid ester, fatty alcohol, sphingosine, ceramide, phosphoglycerolipid, polyisoprenoid, and aryl ether.


4. A vinyl ether lipid compound of the formula





20 wherein one of either  $\text{R}^1$  or  $\text{R}^2$  is a hydrophilic headgroup and the other is hydrogen, a second hydrophilic headgroup, or a crosslinker joining at least one other molecule of the vinyl ether lipid compound at the  $\text{R}^1$  or  $\text{R}^2$  position;  $\text{R}^3$  is an organic hydrophobic moiety; and  $\text{R}^4$  is hydrogen or an electron donating group.

5. The vinyl ether lipid of claim 4, wherein  $R^3$  is selected from the group consisting of cholesterol, a cholesterol derivative, sphingosine, a sphingosine derivative, and a group of the formula

5



wherein each  $R^5$  is independently a hydrophobic group of the formula



, or




10 wherein  $n$  is an integer from 5 to 32 inclusive;  $y$  is an even integer from 2 to 12 inclusive, and wherein  $y$  is less than or equal to  $n$ .

6. The vinyl ether lipid of claim 4, wherein  $R^4$  is selected from the group consisting of  $C_1$ - $C_6$  alkoxy, furan, thiophene, methoxyphenyl, dimethoxyphenyl, and  
15 trimethoxyphenyl.


7. The vinyl ether lipid of claim 4, wherein the hydrophilic headgroup is selected from the group consisting of poly(ethylene glycol),  $C_1$ - $C_6$  alkoxy poly(ethylene glycol), poly(ethylenimine), N,N-di(aminoethyl)carbamyloxyethyl-, choline,  
20 monosaccharide, disaccharide, ethanolamine, phosphatidylcholine,

phosphatidylethanolamine, cardiolipin, phosphatidylmonosaccharides, such as phosphatidylinositol, and phosphatidyl disaccharides.

8. The vinyl ether lipid of claim 7, wherein the hydrophilic headgroup is poly(ethylene glycol), C<sub>1</sub>-C<sub>6</sub> alkoxy poly(ethylene glycol), or N,N-di(aminoethyl)carbamyloxyethyl-.
9. The vinyl ether lipid of claim 8, wherein the hydrophilic headgroup is poly(ethylene glycol) or C<sub>1</sub>-C<sub>6</sub> alkoxy poly(ethylene glycol), and the poly(ethylene glycol) moiety has an average of between 1 and about 300 ethylene glycol units.
10. The vinyl ether lipid of claim 9, wherein the hydrophilic headgroup is poly(ethylene glycol) or C<sub>1</sub>-C<sub>6</sub> alkoxy poly(ethylene glycol), and the poly(ethylene glycol) moiety has an average of between about 10 and about 150 ethylene glycol units.
11. The vinyl ether lipid of claim 8, wherein the of either R<sup>1</sup> or R<sup>2</sup> is poly(ethylene glycol), C<sub>1</sub>-C<sub>6</sub> alkoxy poly(ethylene glycol), or N,N-di(aminoethyl)carbamyloxyethyl-, and the other is hydrogen; and R<sup>3</sup> is selected from the group consisting of cholesterol, a cholesterol derivative, and a group of the formula



wherein each R<sup>5</sup> is independently a hydrophobic group of the formula



, or



wherein n is an integer from 5 to 32 inclusive; y is an even integer from 2 to 12 inclusive, and wherein y is less than or equal to n.

- 5 12. A lipid vesicle comprising at least two different species of lipid compounds, at least one of said lipid compounds being an amphiphilic lipid compound having an acid or oxidatively labile vinyl ether linked hydrophilic headgroup.
- 10 13. The lipid vesicle of claim 12 wherein the molar percent concentration of the amphiphilic lipid compounds having vinyl ether linked hydrophilic headgroups is between about 0.1% and about 20% of the total molar lipid concentration.
- 15 14. The lipid vesicle of claim 13 wherein the molar percent concentration of the amphiphilic lipid compounds having vinyl ether linked hydrophilic headgroups is between about 1% and about 15% of the total molar lipid concentration.
- 20 15. A method of delivering a therapeutic or diagnostic agent to a predetermined *in vivo* tissue or to the interior of a living cell, comprising contacting said tissue or cell with a liposome encapsulating said agent, under acidic or oxidative conditions, said liposome comprising at least two different species of lipid compounds, at least one of said lipid compounds being an amphiphilic lipid compound having an acidically or oxidatively labile vinyl ether linked hydrophilic headgroup, and said acidic or oxidative conditions being effective for cleaving said hydrophilic headgroup from the compound.
- 25 16. A pharmaceutical composition comprising a therapeutic or diagnostic agent encapsulated in a lipid vesicle of claim 12 in a pharmaceutically acceptable carrier.




Fig. 1




Fig. 2



# % Calcein Release from 2%, 4% CVEP:DOPE liposomes





Fig. 3

**% Calcein Release from CVEP:DOPE  
liposomes at pH 2.0**



**Fig. 4**

Percent Calcein Release 2% DVEP: DOPE




Fig. 5

# Percent Calcein release from 2% CVEP, 800nm, 1W/cm<sup>2</sup>





Fig. 6

## 2-Vinyl-1,3-dioxolane Strategy



CMPD	R—Li	SOLVENT	E—X	CIS:TRANS	% YIELD
1	nBuLi	pentane	H <sub>3</sub> O <sup>+</sup>	35:65	71
2	nBuLi	3:2 pentane:ether	H <sub>3</sub> O <sup>+</sup>	65:35	74
3	nBuLi	THF	H <sub>3</sub> O <sup>+</sup>	10:90	15
4	nBuLi	pentane	<i>p</i> -MePhSO <sub>2</sub> —Cl	40:60	81
5	nBuLi	pentane	POCl <sub>3</sub>	35:65	46 (phosphate triester)
6	nBuLi	pentane	(EtO) <sub>2</sub> (O)P—Cl	35:65	90
7	C <sub>10</sub> H <sub>21</sub> —Li	3:2 pentane:ether	H <sub>3</sub> O <sup>+</sup>	70:30	57
8	C <sub>14</sub> H <sub>29</sub> —Li	3:2 pentane:ether	H <sub>3</sub> O <sup>+</sup>	80:20	25

Fig. 7

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/19430

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 9/127

US CL : 554/79; 424/450, 1.21, 9.321, 9.51, 94.3; 935/54

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 554/79; 424/450, 1.21, 9.321, 9.51, 94.3; 935/54

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST

search terms: amphipathic, lipids, vinyl, liposomes, vesicles

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 5,277,913 A (THOMPSON et al) 11 January 1994, abstract, Figures, examples and claims.	1-4, 7 & 12-16 ----- 5-6 & 8-11



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\*

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\*

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\*

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*A\*

document member of the same patent family

Date of the actual completion of the international search

26 SEPTEMBER 2000

Date of mailing of the international search report

14 NOV 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

  
GOLLAMUDI S. KISHORE

Telephone No. (703) 308-1235



32/A

OT/US 00/19430  
IPEA/US 23 AUG 2001

32/1

17. The amphiphilic lipid compound of one of claims 1-11 wherein the hydrophilic headgroup is directly attached to a vinylic carbon atom.

18. The lipid vesicle of one of claims 12-14 wherein the hydrophilic headgroup is directly attached to a vinylic carbon atom.

19. The method of claim 15 wherein the hydrophilic headgroup is directly attached to a vinylic carbon atom.

20. The pharmaceutical composition of claim 16 wherein the hydrophilic headgroup is directly attached to a vinylic carbon atom.

## PATENT COOPERATION TREATY

PCT

FILED 06 NOV 2001

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)


Applicant's or agent's file reference 7024474P116	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/19430	International filing date (day/month/year) 17 JULY 2000	Priority date (day/month/year) 16 JULY 1999
International Patent Classification (IPC) or national classification and IPC IPC(7): A61K 9/127 and US Cl.: 554/79; 424/450, 1.21, 9.321, 9.51, 94.3; 935/54		
Applicant PURDUE RESEARCH CORPORATION		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 4 sheets.
- ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability: citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 13 FEBRUARY 2001	Date of completion of this report 02 OCTOBER 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer  GOLLAMUDI S. KISHORE
Facsimile No. (703) 305-3230	Telephone No. (703) 308-1235

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/19430

**I. Basis of the report****1. With regard to the elements of the international application: \***☐ the international application as originally filed☒ the description:

pages \_\_\_\_\_ (See Attached) \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, filed with the demand  
pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_

☒ the claims:

pages \_\_\_\_\_ (See Attached) \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, as amended (together with any statement) under Article 19  
pages \_\_\_\_\_, filed with the demand  
pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_

☒ the drawings:

pages \_\_\_\_\_ (See Attached) \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, filed with the demand  
pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_

☒ the sequence listing part of the description:

pages \_\_\_\_\_ (See Attached) \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, filed with the demand  
pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application (under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**☐ contained in the international application in printed form.☐ filed together with the international application in computer readable form.☐ furnished subsequently to this Authority in written form.☐ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.**4. ☒ The amendments have resulted in the cancellation of:**☒ the description, pages \_\_\_\_\_ NONE \_\_\_\_\_☒ the claims, Nos. \_\_\_\_\_ NONE \_\_\_\_\_☒ the drawings, sheets/fig \_\_\_\_\_ NONE \_\_\_\_\_**5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\*Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/19430

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. statement

Novelty (N)

Claims 5-6 & 8-11

YES

Claims 1-4, 7 & 12-20

NO

Inventive Step (IS)

Claims 5-6 & 8-11

YES

Claims 1-4, 7 & 12-20

NO

Industrial Applicability (IA)

Claims 1-20

YES

Claims NONE

NO

### 2. citations and explanations (Rule 70.7)

Claims 1-4, 7 and 12-20 lack novelty under PCT Article 33(2) as being anticipated by THOMPSON et al (US 5,277,913).

THOMPSON et al disclose an amphiphilic phospholipid in which the vinyl function is attached to a hydrophilic group, liposomes containing this lipid and a method of delivery (note the abstract, Figures, Examples and claims).

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant in essence argues that unlike in instant compounds, Thompson's compounds have hydrocarbon as R1 and hydrocarbon is not hydrophilic. This argument is not found to be persuasive since on col. 3, line 21 teaches vinyl ethers also instead of hydrocarbons. An ether is formed by a reaction of two hydroxyl groups containing moieties and hydroxyl groups are hydrophilic and therefore, rejected claims read on Thompson.

Claims 5-6 and 8-11 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest instant hydrophilic head groups and because the invention finds its utility in the delivery of agents by a triggered release mechanism.

----- NEW CITATIONS -----  
NONE

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**I. BASIS OF REPORT:**

This report has been drawn on the basis of the description,  
page(s) 1-28, as originally filed.  
page(s) NONE, filed with the demand.  
and additional amendments:  
NONE

This report has been drawn on the basis of the claims,  
page(s) 29-32, as originally filed.  
page(s) NONE, as amended under Article 19.  
page(s) NONE, filed with the demand.  
and additional amendments:  
Claim page 32/1, filed with the letter of 23 August 2001.

This report has been drawn on the basis of the drawings,  
page(s) 1-7, as originally filed.  
page(s) NONE, filed with the demand.  
and additional amendments:  
NONE

This report has been drawn on the basis of the sequence listing part of the description:  
page(s) NONE, as originally filed.  
pages(s) NONE, filed with the demand.  
and additional amendments:  
NONE

## PATENT COOPERATION TREATY

PCT

INFORMATION CONCERNING ELECTED  
OFFICES NOTIFIED OF THEIR ELECTION

(PCT Rule 61.3)

From the INTERNATIONAL BUREAU

To:

HENRY, Thomas, Q.  
Woodard, Emhardt, Naughton,  
Moriarty & McNett  
Bank One Center/Tower  
Suite 3700, 111 Monument Circle  
Indianapolis, IN 46204  
ETATS-UNIS D'AMERIQUE

**RECEIVED**

MAY 21 2001

Woodard, Emhardt, Naughton,  
Moriarty & McNett

Date of mailing (day/month/year) 14 May 2001 (14.05.01)		
Applicant's or agent's file reference 7024474P116		IMPORTANT INFORMATION
International application No. PCT/US00/19430	International filing date (day/month/year) 17 July 2000 (17.07.00)	
Priority date (day/month/year) 16 July 1999 (16.07.99)		
Applicant PURDUE RESEARCH FOUNDATION et al		

1. The applicant is hereby informed that the International Bureau has, according to Article 31(7), notified each of the following Offices of its election:

AP : GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW  
EP : AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
National : AU, BG, CA, CN, CZ, DE, IL, JP, KP, KR, MN, NO, NZ, PL, RO, RU, SE, SK, US

2. The following Offices have waived the requirement for the notification of their election; the notification will be sent to them by the International Bureau only upon their request:

EA : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
OA : BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
National : AE, AG, AL, AM, AT, AZ, BA, BB, BR, BY, BZ, CH, CR, CU, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IN, IS, KE, KG, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, PT, SD, SG, SI, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

3. The applicant is reminded that he must enter the "national phase" before the expiration of 30 months from the priority date before each of the Offices listed above. This must be done by paying the national fee(s) and furnishing, if prescribed, a translation of the international application (Article 39(1)(a)), as well as, where applicable, by furnishing a translation of any annexes of the international preliminary examination report (Article 36(3)(b) and Rule 74.1).

Some offices have fixed time limits expiring later than the above-mentioned time limit. For detailed information about the applicable time limits and the acts to be performed upon entry into the national phase before a particular Office, see Volume II of the PCT Applicant's Guide.

The entry into the European regional phase is postponed until 31 months from the priority date for all States designated for the purposes of obtaining a European patent.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No. (41-22) 740.14.35	Authorized officer:  Claudio Borton  Telephone No. (41-22) 338.83.38
--	--



RECEIVED

PCT/US00/19430

## PATENT COOPERATION TREATY

MAR 21 2001

Woodard, Emhardt, Naughton,  
Moriarty & McNett

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

To:

TUCKER, R., Craig  
Woodard, Emhardt, Naughton,  
Moriarty & McNett  
Bank One Center/Tower  
Suite 3700  
111 Monument Circle  
Indianapolis, IN 46204  
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)

06 March 2001 (06.03.01)

Applicant's or agent's file reference

7024474P116

International application No.

PCT/US00/19430

International filing date (day/month/year)

17 July 2000 (17.07.00)

## IMPORTANT NOTIFICATION

1. The following indications appeared on record concerning:



the applicant



the inventor



the agent



the common representative

Name and Address

PURDUE RESEARCH FOUNDATION  
Office of Technology Transfer  
1063 Hovde Hall  
West Lafayette, IN 47907  
United States of America

State of Nationality

US

State of Residence

US

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:



the person



the name



the address



the nationality



the residence

Name and Address

PURDUE RESEARCH FOUNDATION  
Office of Technology  
Commercialization  
1291 Cumberland Avenue  
West Lafayette, IN 47906  
United States of America

State of Nationality

US

State of Residence

US

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:



the receiving Office



the International Searching Authority



the International Preliminary Examining Authority



the designated Offices concerned



the elected Offices concerned



other:

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

C. Cupello

*Cupello*

Telephone No.: (41-22) 338.83.38

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/19430

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 9/127

US CL : 554/79; 424/450, 1.21, 9.321, 9.51, 94.3; 935/54

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 554/79; 424/450, 1.21, 9.321, 9.51, 94.3; 935/54

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST

search terms: amphipathic, lipids, vinyl, liposomes, vesicles

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	US 5,277,913 A (THOMPSON et al) 11 January 1994, abstract, Figures, examples and claims.	1-4, 7 & 12-16 ----- 5-6 & 8-11

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

*A*	document defining the general state of the art which is not considered to be of particular relevance	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E*	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L*	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O*	document referring to an oral disclosure, use, exhibition or other means	*A*	document member of the same patent family
*P*	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

26 SEPTEMBER 2000

Date of mailing of the international search report

14 NOV 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GOLLAMUDI S KISHORE

Telephone No. (703) 308-1235

## PCT

NOTICE INFORMING THE APPLICANT OF THE  
COMMUNICATION OF THE INTERNATIONAL  
APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

From the INTERNATIONAL BUREAU

To:

TUCKER, R., Craig  
Woodard, Emhardt, Naughton,  
Moriarty & McNett  
Bank One Center/Tower  
Suite 3700  
111 Monument Circle  
Indianapolis, IN 46204  
ETATS-UNIS D'AMERIQUE

RECEIVED

FEB 05 2001

Woodard, Emhardt, Naughton,  
Moriarty & McNettDate of mailing (day/month/year)  
25 January 2001 (25.01.01)Applicant's or agent's file reference  
7024474P116

## IMPORTANT NOTICE

International application No.  
PCT/US00/19430International filing date (day/month/year)  
17 July 2000 (17.07.00)Priority date (day/month/year)  
16 July 1999 (16.07.99)

Applicant

PURDUE RESEARCH FOUNDATION et al

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:  
AU,KP,KR,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:  
AE,AG,AL,AM,AP,AT,AZ,BA,BB,BG,BR,BY,BZ,CA,CH,CN,CR,CU,CZ,DE,DK,DM,DZ,EA,EE,EP,ES,  
FI,GB,GD,GE,GH,GM,HR,HU,ID,IL,IN,IS,JP,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MA,MD,MG,MK,  
MN,MW,MX,MZ,NO,NZ,OA,PL,PT,RO,RU,SD,SE,SG,SI,SK,SL,TJ,TM,TR,TT,TZ,UA,UG,UZ,VN,YU,  
The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).
3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 25 January 2001 (25.01.01) under No. WO 01/05375

## REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

## REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 740.14.35

Authorized officer

J. Zahra

Telephone No. (41-22) 338.83.38

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PATENT COOPERATION TREATY

RECEIVED

PCT

APR 16 2001

To:

R. CRAIG TUCKER  
WOODARD, EMHARDT, NAUGHTON, MORIARTY &  
MCNETT; BANK ONE CENTER/TOWER  
111 MONUMENT CIRCLE, SUITE 3700  
INDIANAPOLIS IN 46204

NOTIFICATION OF RECEIPT  
OF DEMAND BY COMPETENT INTERNATIONAL  
PRELIMINARY EXAMINING AUTHORITY

Woodard, Emhardt, Naughton,  
Moriarty & McNett

(PCT Rule 59.3(e) and 61.1(b), first sentence  
and Administrative Instructions, Section 601(a))

Date of mailing  
(day/month/year)

11 APR 2001

Applicant's or agent's file reference  
7024474P116

IMPORTANT NOTIFICATION

International application No.  
PCT/US00/19430

International filing date (day/month/year)  
17 JUL 00

Priority date (day/month/year)  
16 JUL 99

Applicant

PURDUE RESEARCH FOUNDATION

1. The applicant is hereby **notified** that this International Preliminary Examining Authority considers the following date as the date of receipt of the demand for international preliminary examination of the international application:

13 February 2001 (13.02.01)

2. That date of receipt is:

- ☒ the actual date of receipt of the demand by this Authority (Rule 61.1(b)).  
☐ the actual date of receipt of the demand on behalf of this Authority (Rule 59.3(e)).  
☐ the date on which this Authority has, in response to the invitation to correct defects in the demand (Form PCT/IPEA/404), received the required corrections.

3. ☐ **ATTENTION:** That date of receipt is **AFTER** the expiration of 19 months from the priority date. Consequently, the election(s) made in the demand does (do) not have the effect of postponing the entry into the national phase until 30 months from the priority date (or later in some Offices) (Article 39(1)). Therefore, the acts for entry into the national phase must be performed within 20 months from the priority date (or later in some Offices) (Article 22). For details, see the *PCT Applicant's Guide*, Volume II.

- ☐ (If applicable) This notification confirms the information given by telephone, facsimile transmission or in person on:

4. Only where paragraph 3 applies, a copy of this notification has been sent to the International Bureau.

Name and mailing address of the IPEA/US  
Assistant Commissioner for Patents  
Box PCT  
Washington, D.C. 20231  
Facsimile No.

Attn: IPEA/US

Authorized officer

Telephone No.

703-305-3165

## PATENT COOPERATION TREATY

RECEIVED

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

NOV 09 2001

To: THOMAS Q. HENRY  
WOODARD, EMHARDT, NAUGHTON, MORIARTY  
& MCNETT  
BANK ONE CENTER/TOWER  
111 MONUMENT CIRCLE, SUITE 3700  
INDIANAPOLIS, IN 46204

PCT

Woodard, Emhardt, Naughton,  
Moriarty & McNettNOTIFICATION OF TRANSMITTAL OF  
INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing  
(day/month/year)

05 NOV 2001

Applicant's or agent's file reference

7024474P116

IMPORTANT NOTIFICATION

International application No.

PCT/US00/19430

International filing date (day/month/year)

17 JULY 2000

Priority Date (day/month/year)

16 JULY 1999

Applicant

PURDUE RESEARCH CORPORATION

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

## 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Form PCT/IPEA/416 (July 1992)★

Authorized officer

GOLLAMUDI S. KISHORE

Telephone No. (703) 308-1235

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 7024474P116	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US00/19430	International filing date (day/month/year) 17 JULY 2000	Priority date (day/month/year) 16 JULY 1999
International Patent Classification (IPC) or national classification and IPC IPC(7): A61K 9/127 and US Cl.: 554/79; 424/450, 1.21, 9.321, 9.51, 94.3; 935/54		
Applicant PURDUE RESEARCH CORPORATION		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 4 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability: citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 13 FEBRUARY 2001	Date of completion of this report 02 OCTOBER 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer  GOLLAMUDI S. KISHORE
Facsimile No. (703) 305-3230	Telephone No. (703) 308-1235



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/19430

**I. Basis of the report**

## 1. With regard to the elements of the international application: \*

☐ the international application as originally filed☒ the description:

pages (See Attached) , as originally filed  
pages , filed with the demand  
pages , filed with the letter of

☒ the claims:

pages (See Attached) , as originally filed  
pages , as amended (together with any statement) under Article 19  
pages , filed with the demand  
pages , filed with the letter of

☒ the drawings:

pages (See Attached) , as originally filed  
pages , filed with the demand  
pages , filed with the letter of

☒ the sequence listing part of the description:

pages (See Attached) , as originally filed  
pages , filed with the demand  
pages , filed with the letter of

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.  
These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application (under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:☐ contained in the international application in printed form.☐ filed together with the international application in computer readable form.☐ furnished subsequently to this Authority in written form.☐ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4. ☒ The amendments have resulted in the cancellation of:☒ the description, pages NONE☒ the claims, Nos. NONE☒ the drawings, sheets/fig NONE5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\*Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/19430

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. statement**

Novelty (N)

Claims	<u>5-6 &amp; 8-11</u>	YES
Claims	<u>1-4, 7 &amp; 12-20</u>	NO

Inventive Step (IS)

Claims	<u>5-6 &amp; 8-11</u>	YES
Claims	<u>1-4, 7 &amp; 12-20</u>	NO

Industrial Applicability (IA)

Claims	<u>1-20</u>	YES
Claims	<u>NONE</u>	NO

**2. citations and explanations (Rule 70.7)**

Claims 1-4, 7 and 12-20 lack novelty under PCT Article 33(2) as being anticipated by THOMPSON et al (US 5,277,913).

THOMPSON et al disclose an amphiphilic phospholipid in which the vinyl function is attached to a hydrophilic group, liposomes containing this lipid and a method of delivery (note the abstract, Figures, Examples and claims).

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant in essence argues that unlike in instant compounds, Thompson's compounds have hydrocarbon as R1 and hydrocarbon is not hydrophilic. This argument is not found to be persuasive since on col. 3, line 21 teaches vinyl ethers also instead of hydrocarbons. An ether is formed by a reaction of two hydroxyl groups containing moieties and hydroxyl groups are hydrophilic and therefore, rejected claims read on Thompson.

Claims 5-6 and 8-11 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest instant hydrophilic head groups and because the invention finds its utility in the delivery of agents by a triggered release mechanism.

----- NEW CITATIONS -----  
NONE

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**I. BASIS OF REPORT:**

This report has been drawn on the basis of the description,  
page(s) 1-28, as originally filed.  
page(s) NONE, filed with the demand.  
and additional amendments:  
NONE

This report has been drawn on the basis of the claims,  
page(s) 29-32, as originally filed.  
page(s) NONE, as amended under Article 19.  
page(s) NONE, filed with the demand.  
and additional amendments:  
Claim page 32/1, filed with the letter of 23 August 2001.

This report has been drawn on the basis of the drawings,  
page(s) 1-7, as originally filed.  
page(s) NONE, filed with the demand.  
and additional amendments:  
NONE

This report has been drawn on the basis of the sequence listing part of the description:  
page(s) NONE, as originally filed.  
pages(s) NONE, filed with the demand.  
and additional amendments:  
NONE

17. The amphiphilic lipid compound of one of claims 1-11 wherein the hydrophilic headgroup is directly attached to a vinylic carbon atom.
18. The lipid vesicle of one of claims 12-14 wherein the hydrophilic headgroup is directly attached to a vinylic carbon atom.
19. The method of claim 15 wherein the hydrophilic headgroup is directly attached to a vinylic carbon atom.
20. The pharmaceutical composition of claim 16 wherein the hydrophilic headgroup is directly attached to a vinylic carbon atom.